Rhythm Pharmaceuticals Inc (NASDAQ:RYTM)
| 17.85 Delayed Data As of Jun 02 |  +0.68 / +3.96%Today’s Change | 3.14 Today|||52-Week Range 34.99 | -38.70% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.0B |
Company Description
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Contact Information
Rhythm Pharmaceuticals, Inc. 222 Berkeley Street Boston Massachusetts 02116-3748 |
Employees
Shareholders
| Individual stakeholders | 59.74% |
| Other institutional | 51.98% |
| Mutual fund holders | 47.38% |
Top Executives
| David P. Meeker | Chairman, President & Chief Executive Officer |
| Hunter C. Smith | Chief Financial Officer & Treasurer |
| Brieana Buckley | Vice President-Medical Affairs |
| Joseph Shulman | Chief Technical Officer |
| Yann Mazabraud | Executive Vice President & Head-International |
